

SWEDEN

Recent and planned developments in pharmaceutical policies 2025/2026

CHANGES IN PRICING

Increased WTP for treatment of small patient groups


TLV implemented a new framework which enable accepting higher prices for pharmaceuticals that treat rare conditions in January 2025. It is a stepwise approach where a higher willingness to pay depend on the number of patients in Sweden and the uncertainty regarding effectiveness of the new pharmaceutical.

www.tlv.se/press/nyheter/arkiv/2025-01-15-uppdatering-av-handbok-for-foretag-vid-ansokan-om-subvention-och-pris.html

CHANGES IN REIMBURSEMENT

Patient co-payment in 2026

The Swedish government has decided on changed limits for high-cost coverage. As of January 1, 2026, the ceiling for high-cost coverage for pharmaceuticals will be SEK 3,950 (approx. € 370). Patients pay full price for the medicines included in the high-cost coverage up to SEK 1,475 (approx. € 140). After that, the discount system comes into effect:



www.tlv.se/in-english/medicines/what-is-the-high-cost-threshold/how-it-works.html

OTHER CHANGES

Easier to introduce medicines for small patient groups

The first two joint Nordic medicines with English text were approved in 2025 for use in all Nordic countries, improving access to essential medicines in the small Nordic markets. The first approved medicines are Iqtopam for epilepsy and Mozobil for stem cell transplantation in certain types of cancer.

www.lakemedelsverket.se/sv/nyheter/gemensamma-nordiska-forpackningar-pa-engelska

A new possibility to exclude extemporaneous medication

TLV's regulation regarding extemporaneous medication was updated to make it possible for TLV to decide to exclude a specific substance from being reimbursed. As of yet, no exclusion has been made.

[Ändring i föreskriften som reglerar extemporeläkemedel](#)

New Pharmaceutical Inquiry in Sweden

The Swedish Government has launched a new pharmaceutical inquiry to strengthen and better coordinate the state's responsibility for pharmaceuticals and vaccines. The aim is to improve access, equity and efficiency in a system that is currently fragmented between national and regional actors. The inquiry is due 31st December 2027.

[Read the committee directive here \(in Swedish\)](#)

SPECIAL TOPIC:

Regulation, pricing and reimbursement of pharmaceutical combination products

Regulation exists? No national Regulation is available on evaluation of combination products.

Pricing: No national process is available on pricing of combination products.

Reimbursement: There is no special procedure to evaluate the cost-effectiveness of a combination product at TLV. All combination products are required to be cost-effective as a whole.